MoonLake Immunotherapeutics Class A MLTX 深 滬
等待開盤 09-25 09:30:00 美东时间
12.12
-0.780
-6.05%
華盛通- 最 高12.83
- 今 開12.69
- 成交量 184.11万股
- 最 低 12.04
- 昨 收 12.90
- 總市值 10.31亿
- 52周最高 23.29
- 市盈率 靜 --
- 換手率 2.16%
- 52周最低 8.1773
- 委 比 5.43%
- 總股本 8510.67万
- 歷史最高 64.98
- 量 比 0.95
- 振 幅 6.12%
- 歷史最低 4.25
- 每 手 1
- 風險率 6.47%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
财报速睇 | MoonLake Immunotherapeutics Class A 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损0.62亿美元，同比亏损扩大11.9%
华盛资讯8月10日讯，MoonLake Immunotherapeutics Class A公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损0.62亿美元，同比亏损扩大11.9%。
08-10 20:04
财报速睇 | MoonLake Immunotherapeutics Class A 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损0.62亿美元，同比亏损缩窄11.3%
华盛资讯8月10日讯，MoonLake Immunotherapeutics Class A公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损0.62亿美元，同比亏损缩窄11.3%。
08-10 19:37
MoonLake Immunotherapeutics Reports Topline Results From Phase 3 IZAR-1 Trial Showing Sonelokimab Met All Week 16 Endpoints In Biologic‑Naïve Psoriatic Arthritis Patients
Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimab The primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab’s 60 mg with induction, and significant responses were observed across key secondary endpoints, including ACR20 (...
08-10 19:16
MoonLake Q2 EPS $(0.84) Beats $(0.93) Estimate
MoonLake (NASDAQ:MLTX) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(0.93) by 9.68 percent. This is a 3.45 percent increase over losses of $(0.87) per share from the same period last year.
08-10 19:12
美股大行评级 | 伯恩斯坦上调Robinhood目标价从130美元升至160美元；纽约梅隆银行、Datadog、五三银行、旅行者财产险集团获多家机构上调评级
今日重点评级关注：Needham：维持Immuneering"买入"评级，目标价从11美元升至18美元；富瑞：维持塞德斯医疗"买入"评级，目标价从90美元升至100美元
07-21 11:36
HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $45 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $45 price target.
07-20 19:12
美股大行评级 | 潜在涨幅392.61%！Chardan Capital维持EyePoint"买入"评级，上调目标价至65美元
今日重点评级关注：Chardan Capital：维持EyePoint"买入"评级，目标价从29美元升至65美元；康托·菲茨杰拉德：维持Hyperliquid Strategies"超配"评级，目标价从8美元升至18.4美元
07-02 18:41
Leerink Partners Maintains Outperform on MoonLake, Raises Price Target to $29
Leerink Partners analyst Thomas Smith maintains MoonLake (NASDAQ:MLTX) with a Outperform and raises the price target from $24 to $29.
07-01 21:23
Why Is MoonLake Immunotherapeutics Stock Soaring Monday?
MoonLake Immunotherapeutics (NASDAQ:MLTX) stock is trading higher on Monday after the company reported encouraging 52-week results from its Phase 3 VELA-1 and VELA-2 studies evaluating sonelokimab (SLK) for moderate-to-severe hidradenitis suppurativa (HS). The data released on Sunday showed sustaine...
06-22 20:03
